Virtual care is the new normal around the globe. The emergence of COVID-19 introduced a dual public health emergency in British Columbia. The province was already in the fourth year of its opioid-related overdose crisis. The public health response to COVID-19 must explicitly consider different communities experiencing marginalization including persons with opioid use disorder.
Improving opioid agonist care continuation remains to be a challenge for many community based addiction treatment organizations. Research into effective strategies has used both randomized and non-randomized designs. Is there any difference in treatment dropout between these different study types? (more…)
Gaps in addiction medicine training are a reason for poor substance use care in North America. (more…)
Although opioid agonist treatment is effective in treating opioid use disorders, retention in such treatment is suboptimal in part due to quality of care issues. A new initiative sought to boost treatment of opioid use disorders so that people stay there longer. This article describes how teams did in a structured quality improvement initiative in Vancouver, Canada. (more…)
Canada and the United States (U.S.) face an opioid use disorder and opioid overdose epidemic.
The most effective OUD treatment is opioid agonist therapy (OAT). It means buprenorphine (with and without naloxone) and methadone. Although federal approval for OAT occurred decades ago, in both countries, access to and use of OAT is low. Restrictive policies and complex regulations contribute to limited treatment access. (more…)